Abstract
Mantle cell lymphoma (MCL) is a rare, aggressive, B-cell non-Hodgkin lymphoma. Zanubrutinib, a Bruton’s tyrosine kinase inhibitor (BTKi), was granted accelerated approval by the FDA in November 2019 for the treatment of adult patients with MCL who have received at least 1 prior therapy. This is a cost-minimization analysis of zanubrutinib in this setting from US Medicare and commercial payer perspectives.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
